Sprecher
Marieke van Dalen, Aspen Oss B.V., The Netherlands
Dr Rainer Gnibl, EU-GMP Inspector, Bavarian Government, Germany
Dr Josef Hofer,EXDRA GmbH, Germany
Dr Usfeya A Muazzam, Bonn, Germany
Dr Rainer Gnibl, EU-GMP Inspector, Bavarian Government, Germany
Dr Josef Hofer,EXDRA GmbH, Germany
Dr Usfeya A Muazzam, Bonn, Germany
Zielsetzung
During this Live Online Training you will get to know the relevant aspects of applying for and maintaining a marketing authorisation in the ICH countries. You will learn what you need to know from a GMP perspective about
- the basic requirements for drug approval in Europe, the US and Japan
- the structure of the marketing authorisation dossier according to the CTD
- the input from the GMP regulated departments
- drug approval procedures in the EU and US
- documents to be provided and timelines to be observed
- how to handle changes and variations in the EU, the US and Japan
Hintergrund
For getting a drug approved it is required to demonstrate its quality, efficiency and safety. For that purpose the format of the Common Technical Document (CTD), which is mandatory in Europe since more than 10 years now, has to be used. It is also used to apply for a marketing authorisation in the US and Japan. Therefore a good understanding of the CTD structure is inevitable and a basic requirement for all persons from GMP regulated departments involved in providing and compiling documents for a marketing authorisation application.
For the maintenance of a marketing authorisation it is very important to know how to handle all the changes and variations occurring during the life cycle of a medicinal product. The rules for handling variations in Europe are laid down in the variations regulation (EC) No. 1234/2008 – being applicable as well for national marketing authorisations from August 3rd 2013 – and supporting guidelines. For handling changes in the US rules are provided in different guidances for industry and for approval of changes in Japan there are specific procedures in place to be followed. Maintaining marketing authorisations in a global scenario is a challenge and requires strategic planning and a good knowledge of the different regulations and timelines. Efficient and smooth communication between GMP and Regulatory Affairs is a key factor of success.
For the maintenance of a marketing authorisation it is very important to know how to handle all the changes and variations occurring during the life cycle of a medicinal product. The rules for handling variations in Europe are laid down in the variations regulation (EC) No. 1234/2008 – being applicable as well for national marketing authorisations from August 3rd 2013 – and supporting guidelines. For handling changes in the US rules are provided in different guidances for industry and for approval of changes in Japan there are specific procedures in place to be followed. Maintaining marketing authorisations in a global scenario is a challenge and requires strategic planning and a good knowledge of the different regulations and timelines. Efficient and smooth communication between GMP and Regulatory Affairs is a key factor of success.
Zielgruppe
This Live Online Training is designed for all persons involved in the compilation of pharmaceutical dossiers for global marketing authorisations in the EU and USA. Furthermore the courses will be of interest to personnel from Regulatory Affairs, Quality Assurance, Quality Control and Production and Project Management.
Technical Requirements
For our webinars, we use Cisco WebEx, one of the leading suppliers of online meetings.
At http://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.
Programm
Getting Drugs Approved – What you need to know from a GMP Perspective
What is a regulatory Dossier?
What is a regulatory Dossier?
- Why do we need regulatory dossiers?
- Why are regulatory dossiers binding?
Drug Approvals in the ICH countries: Prerequisites and Procedures
- Centralized procedure / Decentralized procedure
- Mutual Recognition
- National Procedures
- Specific Dossier Requirements for different Medicinal Products
- Time Lines
- Generic Applications
- New Drug Application (NDA)
- IND procedure and special issues
- Abbreviated New Drug Application (ANDA) – Generics
- Pre-approval inspections
- Timelines and meetings with the FDA
- Regulatory Requirements in Japan
- GMP Regulations in Japan (J-GMP)
CTD Module 1- Summary of Product Characteristics and other national Requirements
- Quality related aspects of the SmPC
- Clinical particulars
- Pharmacological properties
- Pharmaceutical particulars
- Labelling
- Package Leaflet
- Mock ups and Specimen
- Quality Experts, Non Clinical and Clinical Experts
- Bibliographical applications
- Homeopathic Applications
- Pediatric Applications
CTD Module 2- The Quality Overall Summary: Importance and Benefits
- Regulatory background of QOS
- Benefits (and why you can call it „Queen of Submission“)
- Frequent deficiencies, examples
- Optimising the submission
CTD Module 3 – Quality of the Drug Product: relevant GMP Documents
- Medicinal product – documentation of quality in Module 3
- Impurities
- Stability data
- Container and closure systems
- Critical parameters
- Optimising the submission
- Risk based approach in industry and regulatory authority
CTD Module 3- How to document Drug Substance Quality – Certificate of Suitability (CEP) and Active Substance Master File (ASMF)
- Documentation of drug substance quality in Module 2
- The Quality Overall Summary (QOS)
- CEP and ASMF procedure – how they work in principle
- Types and format of ASMFs
- Contents of the applicants part and the restricted part
- How to apply for a CEP
- Dossier Content
- CEP assessment and CEP inspections
- DMF procedures in US and Japan
CTD Modules 4 and 5- non clinical and clinical Documentation: GMP, GCP and GLP Aspects
- Clinical study reports
- Efficacy and safety
- Clinical summary and clinical overview
- Non clinical study reports
- Toxicology
- Pharmacokinetics
- Safety studies – decision tree
- Toxicity studies to qualify impurities
- Non clinical summary
- Critical points
Regulatory Compliance Aspects during Authority Inspections
- Types of inspections
- Essential PQS interfaces
- Change control from a GMP view
- Deviations from Marketing Authorisations
- Inspector’s planning, preparation, conduction and follow-up of GMP inspections
Technical Terms of GMP Inspections – EU-GMP Requirements
- EU-GMP regulations
- Technical terms of EU-GMP guidelines
- Basic requirements for GMP inspections
Maintaining a Marketing Authorisation – The Interaction between GMP and Regulatory Affairs
Handling Changes in the ICH countries
Handling Changes in the ICH countries
- Starting a change in your company
- The variations procedure in Europe
- General provisions of the Commission Regulation (EC) No 1234/2008
- Supporting Guidelines
- Best Practice Guides and Explanatory Notes
- Classification of variations
- Procedural handling of variations; Grouping, Worksharing
- Handling Changes in the US: Changes to an approved NDA and ANDA
- Types of changes
- Change control procedure and reporting mechanisms
- Handling changes in Japan: Change procedures and communication with the Japanese authority
- Types of changes
- Notification of changes
Dieses Seminar/Webinar kann nicht gebucht werden. Alternative Termine für dieses Seminar/Webinar und ähnliche Veranstaltungen finden Sie in der Übersicht nach Thema..
Für viele Seminare und Webinare gibt es auch Aufzeichnungen, die Sie jederzeit bestellen und anschauen können. Diese Aufzeichnungen finden Sie in einer themensortierten Liste.
Oder senden Sie uns Ihre Anfrage einfach über das folgende Kontaktformular.
* auch unkompliziert per Kreditkarte bezahlbar
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
Weitere Termine online
Weitere Termine online nicht verfügbar
Aufzeichnung nicht verfügbar
Haben Sie noch Fragen?
Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
Tel.: +49 6221 84 44 0
E-Mail: info@concept-heidelberg.de
Teilnehmerstimmen - das sagen andere über unsere Seminare:
